Clinical Trials Logo

Radiotherapy clinical trials

View clinical trials related to Radiotherapy.

Filter by:

NCT ID: NCT03503682 Recruiting - Palliative Care Clinical Trials

Short Course Radiation Therapy in Palliative Treatment of Complicated Bone Metastases

Start date: November 8, 2017
Phase: N/A
Study type: Interventional

Aim of the study is to assess efficacy of a short course radiation treatment in patients with complicated bone metastases

NCT ID: NCT03479814 Recruiting - Rectal Cancer Clinical Trials

Adaptive Individualized High-Dose Radiotherapy Analysis-REctum-1 (AIDA-RE-1)

Start date: August 1, 2016
Phase: N/A
Study type: Interventional

Aim of the study is to evaluate achievement of complete pathologic response (pCR) in high-risk rectal cancer treated with neoadjuvant concomitant chemotherapy plus adaptive-intensity modulated imaging-guided radiotherapy

NCT ID: NCT03461822 Recruiting - Radiotherapy Clinical Trials

Effectiveness of Stereotactic RadioTherapy in Solid Primary Inoperable and Oligometastatic Cancer

ESRTSPIOC
Start date: March 2013
Phase: N/A
Study type: Observational

The purpose of this study is to development of more effective treatment tactics of the stereotactic radiotherapy and radiosurgery alone and together with classic radiation therapy in primary inoperabel solid tumors and oligometastastatic cancer.

NCT ID: NCT03431740 Terminated - Radiotherapy Clinical Trials

FENO, Extended NO Analysis and NO/CO Diffusing Capacity in Thoracic Radiation Therapy

Start date: February 15, 2018
Phase:
Study type: Observational

The investigators aim to investigate the impact of thoracic radiation therapy on diffusion capacity of the lung (primary endpoint: diffusion capacity for nitric oxide, DLNO) and on exhaled nitric oxide.

NCT ID: NCT03416803 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular Carcinoma

Start date: February 2018
Phase: N/A
Study type: Interventional

Objectives: 1. To further validate the predictive efficacy of our established microRNA prediction model of HCC lymph node metastasis. 2. To establish a precise therapeutic mode of prophylactic radiation therapy in high-risk patients with HCC with lymph node metastasis under the guidance of a microRNA prediction model.

NCT ID: NCT03370926 Recruiting - Clinical trials for Glioblastoma Multiforme

FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy

IMAGG
Start date: October 31, 2016
Phase: N/A
Study type: Observational

Glioblastoma is the most common malignant brain tumor in adults. The primary treatment consists of maximal tumor removal followed by radiotherapy (RT) with concomitant and adjuvant temozolomide. Tumor recurrence after chemoradiotherapy has previously been shown to be predominantly within or at the margin of the irradiated volume, but distant failure are not rare, especially in patients with MGMT methylation.Traditionally, RT has been planned based on on planning CT with co-registered postoperative MRI, with the addition of a clinical target volume margin of 2-3 cm to account for infiltrative odema. To better characterize the disease, more specific physiological and/or metabolical markers of tumor cells, vascularization and hypoxia measured on multiparametric MRI as perfusion, diffusion and spectroscopy alongside with PET tracer like Fluoroéthyl-L-tyrosine ([18F]-FET) are now available and suggest that aggressive areas, like uptake of PET tracer and vascularity are present outside areas of contrast enhancement usually irradiated. These informations could be incorporated to optimize the treatment of radiotherapy.

NCT ID: NCT03338075 Completed - Brain Metastases Clinical Trials

FSRT Combined With TMZ for Large BMs: a PSM Study

Start date: January 1, 2016
Phase: N/A
Study type: Observational

A propensity- matched study was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.

NCT ID: NCT03280719 Completed - Breast Neoplasms Clinical Trials

Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions

PRO-SURF
Start date: September 15, 2017
Phase: N/A
Study type: Interventional

The goal of this trial is to evaluate the effect of the prone crawl treatment position and/or accelerated schedule on acute and late toxicities, as well as quality of life and time management for breast cancer patients receiving whole breast and regional nodal irradiation after breast conserving surgery.

NCT ID: NCT03214003 Completed - Radiotherapy Clinical Trials

Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

TRISS
Start date: June 30, 2017
Phase: N/A
Study type: Interventional

This trial is a multicenter, perspective, non-blinded, randomized controlled phase 3 trial. In order to establish whether the SIB technique can improve the results of twice-daily chemo-RT for patients with LS-SCLC, the investigators will primarily compare survival of patients treated with standard chemotherapy (cisplatin and etoposide) and either SIB twice-daily RT or standard dose twice-daily RT.

NCT ID: NCT03212742 Recruiting - Radiotherapy Clinical Trials

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

OLA-TMZ-RTE-01
Start date: September 4, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The Stupp protocol is the standard treatment of glioblastoma multiform (GBM) which prognosis remains poor. The non-dividing nature of normal brain cells provides an opportunity to enhance the therapeutic ratio by combining radiation with inhibitors of replication-specific DNA repair pathways such poly(ADP-ribose) polymerase (PARP) inhibitors, thus inducing more cytotoxic effects of DNA-damage related to treatment modalities, including alkylating reagents like temozolomide (TMZ). Olaparib, a potent PARP inhibitor, overcomes apoptotic resistance and sensitizes GBM cells for death receptor-mediated apoptosis induced by TRAIL (Tumor necrosis factor-Related Apoptosis Inducing Ligand). Moreover, inhibition of PARP activity increases cellular sensitivity to ionizing radiation: it was even suggested to be more pronounced in tumors than in normal tissue. Lastly, progress in technical imaging and intensity-modulated-radiotherapy (IMRT) techniques provide new possibilities for sparing healthy tissues.